PTPRO

Protein identityUniProt · HPA

UniProt accession

Q16827

Gene

PTPRO

Ensembl

ENSG00000151490

Chromosome

12

Canonical length

1216 aa

Protein class

Cancer-related genes, Disease related genes, Enzymes, Human disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins

Secretome location

Intracellular and membrane

OverviewNCBI Gene

This gene encodes a member of the R3 subtype family of receptor-type protein tyrosine phosphatases. These proteins are localized to the apical surface of polarized cells and may have tissue-specific functions through activation of Src family kinases. This gene contains two distinct promoters, and alternatively spliced transcript variants encoding multiple isoforms have been observed. The encoded proteins may have multiple isoform-specific and tissue-specific functions, including the regulation of osteoclast production and activity, inhibition of cell proliferation and facilitation of apoptosis. This gene is a candidate tumor suppressor, and decreased expression of this gene has been observed in several types of cancer. [provided by RefSeq, May 2011]

Canonical amino-acid sequenceUniProt

1216 residues, UniProt reviewed canonical sequence.

>Q16827|PTPRO
     1  MGHLPTGIHG ARRLLPLLWL FVLFKNATAF HVTVQDDNNI VVSLEASDVI SPASVYVVKI
    61  TGESKNYFFE FEEFNSTLPP PVIFKASYHG LYYIITLVVV NGNVVTKPSR SITVLTKPLP
   121  VTSVSIYDYK PSPETGVLFE IHYPEKYNVF TRVNISYWEG KDFRTMLYKD FFKGKTVFNH
   181  WLPGMCYSNI TFQLVSEATF NKSTLVEYSG VSHEPKQHRT APYPPQNISV RIVNLNKNNW
   241  EEQSGNFPEE SFMRSQDTIG KEKLFHFTEE TPEIPSGNIS SGWPDFNSSD YETTSQPYWW
   301  DSASAAPESE DEFVSVLPME YENNSTLSET EKSTSGSFSF FPVQMILTWL PPKPPTAFDG
   361  FHIHIEREEN FTEYLMVDEE AHEFVAELKE PGKYKLSVTT FSSSGSCETR KSQSAKSLSF
   421  YISPSGEWIE ELTEKPQHVS VHVLSSTTAL MSWTSSQENY NSTIVSVVSL TCQKQKESQR
   481  LEKQYCTQVN SSKPIIENLV PGAQYQVVIY LRKGPLIGPP SDPVTFAIVP TGIKDLMLYP
   541  LGPTAVVLSW TRPYLGVFRK YVVEMFYFNP ATMTSEWTTY YEIAATVSLT ASVRIANLLP
   601  AWYYNFRVTM VTWGDPELSC CDSSTISFIT APVAPEITSV EYFNSLLYIS WTYGDDTTDL
   661  SHSRMLHWMV VAEGKKKIKK SVTRNVMTAI LSLPPGDIYN LSVTACTERG SNTSMLRLVK
   721  LEPAPPKSLF AVNKTQTSVT LLWVEEGVAD FFEVFCQQVG SSQKTKLQEP VAVSSHVVTI
   781  SSLLPATAYN CSVTSFSHDS PSVPTFIAVS TMVTEMNPNV VVISVLAILS TLLIGLLLVT
   841  LIILRKKHLQ MARECGAGTF VNFASLERDG KLPYNWRRSI FAFLTLLPSC LWTDYLLAFY
   901  INPWSKNGLK KRKLTNPVQL DDFDAYIKDM AKDSDYKFSL QFEELKLIGL DIPHFAADLP
   961  LNRCKNRYTN ILPYDFSRVR LVSMNEEEGA DYINANYIPG YNSPQEYIAT QGPLPETRND
  1021  FWKMVLQQKS QIIVMLTQCN EKRRVKCDHY WPFTEEPIAY GDITVEMISE EEQDDWACRH
  1081  FRINYADEMQ DVMHFNYTAW PDHGVPTANA AESILQFVHM VRQQATKSKG PMIIHCSAGV
  1141  GRTGTFIALD RLLQHIRDHE FVDILGLVSE MRSYRMSMVQ TEEQYIFIHQ CVQLMWMKKK
  1201  QQFCISDVIY ENVSKS

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against PTPRO can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability

Cell surface

Secreted

No

Transmembrane segments

1

Mean surface accessibility (rSASA)

0.35

Highest tissue expression

32 nTPM

Expression across tissuesHPA

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about PTPRO.

Disease | AllUniProt

Conditions PTPRO is implicated in, by any mechanism.

• Nephrotic syndrome 6 (NPHS6) MIM:614196

Disease | GeneticClinVar

10 pathogenic / likely-pathogenic of 547 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

• Nephrotic syndrome, type 6

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)

0.47

gnomAD pLI

0

gnomAD missense Z

1.3

DepMap mean gene effect

0.07

DepMap dependency class

none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

• axon guidance
• cell morphogenesis
• glomerulus development
• lamellipodium assembly
• monocyte chemotaxis
• negative regulation of canonical Wnt signaling pathway
• negative regulation of cell-substrate adhesion
• negative regulation of glomerular filtration
• negative regulation of neuron projection development
• negative regulation of retinal ganglion cell axon guidance
• podocyte differentiation
• regulation of glomerular filtration
• regulation of synapse organization
• slit diaphragm assembly

Molecular functions

• cadherin binding
• phosphatase activity
• protein homodimerization activity
• protein tyrosine phosphatase activity
• transmembrane receptor protein tyrosine phosphatase activity
• Wnt-protein binding

Cellular components

• apical plasma membrane
• axon
• dendritic spine
• extracellular exosome
• GABA-ergic synapse
• glutamatergic synapse
• growth cone
• lamellipodium
• lateral plasma membrane
• membrane
• neuron projection
• plasma membrane
• postsynaptic density membrane

Protein domainsUniProt · Pfam · InterPro

• Tyrosine-specific protein phosphatase, PTPase domain
• Tyrosine-specific protein phosphatases domain
• Protein-tyrosine phosphatase, catalytic
• Fibronectin type III
• Immunoglobulin-like fold
• Protein-tyrosine phosphatase, active site
• Protein-tyrosine phosphatase-like
• Fibronectin type III superfamily
• Fibronectin type III domain
• Protein-tyrosine phosphatase
• Receptor-type tyrosine-protein phosphatase O
• R-PTP-O-like, Fn3 domain
• R-PTP-O-like, fibronectin type III domain

KeywordsUniProt

• Glycoprotein
• Hydrolase
• Membrane
• Phosphoprotein
• Protein phosphatase
• Receptor
• Repeat
• Signal
• Transmembrane
• Transmembrane helix

InteractionsUniProt · HPA

Protein binding partners of PTPRO in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

• GRB2
• FYN